nodes	percent_of_prediction	percent_of_DWPC	metapath
Gallamine Triethiodide—Salivary gland enlargement—Riluzole—amyotrophic lateral sclerosis	0.0902	0.139	CcSEcCtD
Gallamine Triethiodide—Polyp—Riluzole—amyotrophic lateral sclerosis	0.0412	0.0636	CcSEcCtD
Gallamine Triethiodide—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.0382	0.059	CcSEcCtD
Gallamine Triethiodide—ACHE—Acetylcholine Synthesis—CHAT—amyotrophic lateral sclerosis	0.0381	0.108	CbGpPWpGaD
Gallamine Triethiodide—Cyst—Riluzole—amyotrophic lateral sclerosis	0.0375	0.0579	CcSEcCtD
Gallamine Triethiodide—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.0302	0.0467	CcSEcCtD
Gallamine Triethiodide—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.0226	0.035	CcSEcCtD
Gallamine Triethiodide—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.0213	0.0329	CcSEcCtD
Gallamine Triethiodide—ACHE—Biogenic Amine Synthesis—CHAT—amyotrophic lateral sclerosis	0.0207	0.0587	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.019	0.0537	CbGpPWpGaD
Gallamine Triethiodide—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0182	0.0281	CcSEcCtD
Gallamine Triethiodide—ACHE—Synthesis of PC—CHAT—amyotrophic lateral sclerosis	0.0171	0.0486	CbGpPWpGaD
Gallamine Triethiodide—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0151	0.0233	CcSEcCtD
Gallamine Triethiodide—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0149	0.023	CcSEcCtD
Gallamine Triethiodide—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0195	CcSEcCtD
Gallamine Triethiodide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0195	CcSEcCtD
Gallamine Triethiodide—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0194	CcSEcCtD
Gallamine Triethiodide—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.0125	0.0193	CcSEcCtD
Gallamine Triethiodide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0182	CcSEcCtD
Gallamine Triethiodide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0117	0.018	CcSEcCtD
Gallamine Triethiodide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0166	CcSEcCtD
Gallamine Triethiodide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0156	CcSEcCtD
Gallamine Triethiodide—ACHE—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.0101	0.0285	CbGpPWpGaD
Gallamine Triethiodide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.01	0.0155	CcSEcCtD
Gallamine Triethiodide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00987	0.0153	CcSEcCtD
Gallamine Triethiodide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.0098	0.0151	CcSEcCtD
Gallamine Triethiodide—Cough—Riluzole—amyotrophic lateral sclerosis	0.00955	0.0148	CcSEcCtD
Gallamine Triethiodide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00932	0.0144	CcSEcCtD
Gallamine Triethiodide—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00932	0.0144	CcSEcCtD
Gallamine Triethiodide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00926	0.0143	CcSEcCtD
Gallamine Triethiodide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00901	0.0139	CcSEcCtD
Gallamine Triethiodide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00875	0.0135	CcSEcCtD
Gallamine Triethiodide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00872	0.0135	CcSEcCtD
Gallamine Triethiodide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00868	0.0134	CcSEcCtD
Gallamine Triethiodide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00814	0.0126	CcSEcCtD
Gallamine Triethiodide—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00802	0.0124	CcSEcCtD
Gallamine Triethiodide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00771	0.0119	CcSEcCtD
Gallamine Triethiodide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.0077	0.0119	CcSEcCtD
Gallamine Triethiodide—Pain—Riluzole—amyotrophic lateral sclerosis	0.00764	0.0118	CcSEcCtD
Gallamine Triethiodide—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.0074	0.021	CbGpPWpGaD
Gallamine Triethiodide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00736	0.0114	CcSEcCtD
Gallamine Triethiodide—ACHE—Phospholipid metabolism—SACM1L—amyotrophic lateral sclerosis	0.00718	0.0204	CbGpPWpGaD
Gallamine Triethiodide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.0071	0.011	CcSEcCtD
Gallamine Triethiodide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00706	0.0109	CcSEcCtD
Gallamine Triethiodide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00706	0.0109	CcSEcCtD
Gallamine Triethiodide—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.00682	0.0194	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Phospholipid metabolism—FIG4—amyotrophic lateral sclerosis	0.00675	0.0191	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Glycerophospholipid biosynthesis—PLB1—amyotrophic lateral sclerosis	0.00663	0.0188	CbGpPWpGaD
Gallamine Triethiodide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00658	0.0102	CcSEcCtD
Gallamine Triethiodide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00641	0.0099	CcSEcCtD
Gallamine Triethiodide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00632	0.00976	CcSEcCtD
Gallamine Triethiodide—ACHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—amyotrophic lateral sclerosis	0.00629	0.0178	CbGpPWpGaD
Gallamine Triethiodide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00611	0.00944	CcSEcCtD
Gallamine Triethiodide—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.00603	0.0171	CbGpPWpGaD
Gallamine Triethiodide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00568	0.00878	CcSEcCtD
Gallamine Triethiodide—Rash—Riluzole—amyotrophic lateral sclerosis	0.00563	0.0087	CcSEcCtD
Gallamine Triethiodide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00563	0.00869	CcSEcCtD
Gallamine Triethiodide—Headache—Riluzole—amyotrophic lateral sclerosis	0.0056	0.00865	CcSEcCtD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00556	0.0158	CbGpPWpGaD
Gallamine Triethiodide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00531	0.0082	CcSEcCtD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00513	0.0145	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Glycerophospholipid biosynthesis—CHAT—amyotrophic lateral sclerosis	0.00503	0.0143	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.00496	0.0141	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00495	0.014	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Phospholipid metabolism—PLB1—amyotrophic lateral sclerosis	0.00463	0.0131	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00453	0.0129	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00426	0.0121	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00421	0.0119	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00421	0.0119	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.0042	0.0119	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00393	0.0111	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.0038	0.0108	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00376	0.0106	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	0.00351	0.00994	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00347	0.00985	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00344	0.00975	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00342	0.0097	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00335	0.0095	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00323	0.00915	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00323	0.00915	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00317	0.009	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	0.0031	0.00879	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00306	0.00869	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00288	0.00816	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.0028	0.00795	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00272	0.00771	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00263	0.00747	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00261	0.00739	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00261	0.00739	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Regulation of Actin Cytoskeleton—PFN1—amyotrophic lateral sclerosis	0.00255	0.00724	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00249	0.00705	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Glycerophospholipid biosynthesis—PLA2G4A—amyotrophic lateral sclerosis	0.00248	0.00704	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00243	0.00689	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00235	0.00667	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	0.00235	0.00666	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00235	0.00666	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00232	0.00659	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00231	0.00656	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.00228	0.00647	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00217	0.00616	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00216	0.00612	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00216	0.00612	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00216	0.00612	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.00215	0.00609	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.00215	0.00609	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00215	0.00609	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.002	0.00566	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.002	0.00566	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.00178	0.00505	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00178	0.00505	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	0.00174	0.00492	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00173	0.00491	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.00166	0.00471	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.00156	0.00441	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00149	0.00422	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.00147	0.00416	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.0014	0.00397	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.00134	0.00379	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00124	0.00351	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.00123	0.0035	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00121	0.00343	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00121	0.00343	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00113	0.0032	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.00112	0.00317	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00111	0.00314	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.00105	0.00298	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00103	0.00292	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000968	0.00274	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000942	0.00267	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000908	0.00257	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—DAO—amyotrophic lateral sclerosis	0.000875	0.00248	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.000775	0.0022	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000753	0.00213	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000699	0.00198	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000679	0.00193	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000663	0.00188	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—GSR—amyotrophic lateral sclerosis	0.000612	0.00174	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000593	0.00168	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000558	0.00158	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000558	0.00158	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.00054	0.00153	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000532	0.00151	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000503	0.00143	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000484	0.00137	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000474	0.00134	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000459	0.0013	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000448	0.00127	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000411	0.00117	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000377	0.00107	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000354	0.001	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000336	0.000952	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	0.000328	0.000929	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000325	0.000922	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000314	0.000891	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000289	0.000819	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000286	0.00081	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.00027	0.000766	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000248	0.000704	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000239	0.000677	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000232	0.000659	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000211	0.000598	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—APOE—amyotrophic lateral sclerosis	0.000204	0.000579	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000196	0.000556	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000184	0.000522	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000175	0.000497	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.00015	0.000425	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000141	0.0004	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.00014	0.000397	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000125	0.000354	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000116	0.000329	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.59e-05	0.000272	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.38e-05	0.000209	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.98e-05	0.000198	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.26e-05	0.000178	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.73e-05	0.000134	CbGpPWpGaD
